Spyre Therapeutics, Inc. (SYRE) financials

Spyre Therapeutics, Inc. (SYRE) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2025, Spyre Therapeutics, Inc. reported revenue of $0 and net income of -$155M.

Revenue (fiscal 2025)

$0

Net income (fiscal 2025)

-$155M

Spyre Therapeutics, Inc. files with the U.S. Securities and Exchange Commission under CIK 0001636282, classified as Pharmaceutical Preparations.

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.